Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1552W HIGH $4.50
Volume
3.38 K
Value Traded
23.95 K
Short % Float
2.95%
-6.75%Week
-13.33%1 Month
-28.48%3 Month
-3.49%6 Month
-97.62%5 Year
-99.92%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.67 M
EPS (TTM)
-0.18
P/E Ratio
-
Ent. Value
6.16 M
Total Shares
4.85 M
Float Shares
4.95 M
Insiders
0.56%
Institutions
1.34%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BLRX Catalyst Timeline
Dated clinical, regulatory and corporate events for BioLineRx Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioLineRx Ltd.
145Total events
9Upcoming
41Tier-1 (high impact)
2011 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Trial InitiationGLIX1Trial
Third patient cohort expected to commence dosing in Phase 1/2a trial of GLIX1 in GBM
glioblastomasource ↗
▼Equity OfferingCorporate
Definitive agreement for offering with gross proceeds of $3.75 million expected to close
▲Preclinical PoCGLIX1Preclinical
GLIX1 and PARP inhibitor showed strong synergy in HR-proficient ovarian cancer PDX model
ovarian cancersource ↗
◆Partnership / LicenseGLIX1Corporate
Discussions initiated with PARP inhibitor companies for potential collaborations
▲Preclinical PoCGLIX1Preclinical
Preclinical data demonstrating synergy between GLIX1 and PARP inhibitor olaparib in PDX model
ovarian cancersource ↗
▲First Patient DosedGLIX1Trial
Second cohort dosing commenced in Phase 1/2a trial of GLIX1 in GBM
glioblastomasource ↗
●Quarterly UpdateAPHEXDAApprovedCorporate
APHEXDA Q2 2026 sales of $1.6 million
stem cell mobilizationsource ↗
◆Poster PresentationGLIX1Presentation
Two abstracts featuring GLIX1 to be published at ASCO 2026
●Trial InitiationGLIX1Trial
Phase 1/2a clinical trial of GLIX1 initiated
recurrent or progressive high-grade glioma and other solid tumorssource ↗
◆Poster PresentationPresentation
Poster presentation of pilot phase data from CheMo4METPANC trial at ASCO 2025
first-line pancreatic cancer (PDAC)source ↗
▲Patent GrantedIP / Competition
USPTO Notice of Allowance for composition of matter patent on motixafortide extending protection through December 2041
▲Debt Royalty FinancingCorporate
BioLineRx draws down second tranche of $20 million under non-dilutive debt financing agreement with BlackRock
▼Equity OfferingCorporate
BioLineRx completed registered direct equity offering raising $6 million
◆Trial InitiationAPHEXDAApprovedTrial
Initiation of bridging study by Gloria Biosciences to support approval of APHEXDA in stem cell mobilization for multiple myeloma in China
stem cell mobilization for multiple myelomasource ↗
◆Enrollment CompleteTrial
Completion of recruitment in Phase 1 pilot study of motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease
sickle cell disease (hematopoietic stem cell mobilization for gene therapies)source ↗
◆Topline ReadoutClinical Data
Initial data expected from Phase 1 pilot study of motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease
sickle cell disease (hematopoietic stem cell mobilization for gene therapies)source ↗
◆Enrollment UpdateTrial
Continued recruitment in Chemo4MetPanc Phase 2b randomized clinical trial in first-line metastatic pancreatic cancer
first-line metastatic pancreatic cancersource ↗
◆Trial InitiationTrial
Preparation activities with Gloria Biosciences on a randomized Phase 2b clinical trial evaluating motixafortide in combination with zimberelimab and chemotherapy in first-line pancreatic cancer
first-line pancreatic cancersource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement with Gloria Biosciences for Asia
stem cell mobilization; pancreatic cancersource ↗
▲Oral PresentationPresentation
Preliminary data from single-arm pilot phase reported at AACR Special Conference on Pancreatic Cancer
pancreatic cancersource ↗
◆Oral PresentationPresentation
Oral presentation of pilot phase data at AACR Special Conference on Pancreatic Cancer
first-line pancreatic cancer (PDAC)source ↗
▲Topline ReadoutClinical Data
Pilot phase data: 6 of 11 patients partial response, 4 confirmed
first-line pancreatic cancer (PDAC)source ↗
◆PDUFA DateRegulatory Filing
PDUFA date of September 9, 2023 for motixafortide NDA
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
▲FDA ApprovalAPHEXDAApprovedFDA Decision
FDA approval of APHEXDA (motixafortide) in combination with G-CSF
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
▲FDA ApprovalAPHEXDAApprovedFDA Decision
FDA approval of APHEXDA (motixafortide) for stem cell mobilization
stem cell mobilization in autologous stem cell transplantation in multiple myelomasource ↗
◆Product LaunchPost-Market
Potential U.S. commercial launch in September 2023
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement for Motixafortide in Asia region with concurrent equity investment
Stem cell mobilization and pancreatic cancersource ↗
▲Trial InitiationTrial
Initiation of investigator-initiated randomized Phase 2 combination trial with Motixafortide in first line PDAC in collaboration with Columbia University
First-line metastatic pancreatic ductal adenocarcinoma (PDAC)source ↗
●Poster PresentationPresentation
Poster of amended trial design presented at ASCO 2023
first-line pancreatic cancer (PDAC)source ↗
▲Full ResultsClinical Data
Publication of GENESIS Phase 3 trial data in Nature Medicine
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
●NDA SubmissionRegulatory Filing
NDA for motixafortide accepted and under review by FDA
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
▲PublicationPresentation
Publication in Nature Medicine of GENESIS Phase 3 clinical trial data
stem cell mobilization for autologous transplantation in multiple myelomasource ↗
▲Enrollment UpdateTrial
Trial amended to randomized study, enrollment increased to 102 patients
first-line pancreatic cancer (PDAC)source ↗
◆Trial InitiationTrial
Anticipated clinical trial initiation for motixafortide in sickle cell disease
Sickle cell disease (stem cell mobilization for gene therapy)source ↗
◆Topline ReadoutClinical Data
Anticipated initial patient data from Columbia University investigator-initiated Phase 2 study
first-line metastatic pancreatic ductal adenocarcinomasource ↗
●Trial InitiationAPHEXDAApprovedTrial
Randomized phase 2b study with 200 patients in combination with PD1 and chemotherapy as first-line PDAC therapy to initiate
first-line pancreatic cancer (PDAC)source ↗
●NDA SubmissionAPHEXDAApprovedRegulatory Filing
NDA submission completed for APHEXDA
stem cell mobilization in autologous bone marrow transplantation for multiple myelomasource ↗
●Pre NDA MeetingAPHEXDAApprovedFDA Meeting
Pre-NDA meeting with FDA completed
stem cell mobilization in autologous bone marrow transplantation for multiple myelomasource ↗
▼Equity OfferingCorporate
Closing of $34.5 million bought deal offering and full exercise of underwriter option
▲EU Orphan DesignationEx-US Regulatory
EC granted Orphan Drug Designation for Motixafortide for pancreatic cancer
pancreatic cancersource ↗
◆Topline ReadoutClinical Data
Results from triple combination arm expected in second half of 2019
metastatic pancreatic cancersource ↗
▲Orphan Drug DesignationDesignation
FDA grants Orphan Drug Designation to BL-8040 for pancreatic cancer
pancreatic cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How BLRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-01 | GLIX1 | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$0M
Pipeline Value
$1M
Commercial Value
Richly Valued
Valuation Signal
6
Drugs Scored
-
rNPV / MCap
Top 87%
Micro Cap(rank 573 of 658)
Percentile Rank
BioLineRx Ltd. faces pipeline headwinds (23/100), with 6 assets in development.
Commercial products (revenue basis: latest annual revenue in its 20-F, to Dec 2025) Revenue $1.2M x 1.0 = $1M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every BLRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| GLIX1 | glioblastoma | Phase 1/2a | 2026-08-31 | GLIX1 achieved potent antitumor activity in TMZ-resistant patient-derived xenograft (PDX) GBM in vivo model; strong synergistic effect between GLIX1 and PARP inhibitor in patient-derived HR-proficient ovarian cancer xenograft modelRead More | BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BLRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.1 % | 267.00 K | 288.85 K | 1.19% ( 3.40 K) |
BLRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BLRX ranks across every disease it competes in
Competitive Position is a premium feature
See how BLRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBLRX News
BLRX▼ -0.5%today
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx and Hemispherian announced two presentations on GLIX1 at the 31st SNO Annual Meeting. These presentations will cover preclinical research and the ongoing Phase 1/2a clinical trial for GLIX1 in patients with recurrent high-grade glioma. The event is scheduled for November 12-15, 2026, in Philadelphia.
Read more →BLRXBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx and Hemispherian AS will present promising preclinical data for GLIX1 at the EANO 2026 conference. The data showcases GLIX1's anti-tumor efficacy in glioblastoma models and outlines the design of an ongoing Phase 1/2a clinical trial. This trial aims to evaluate GLIX1's safety and efficacy in patients with recurrent or progressive high-grade glioma.
Read more →BLRX▲ +7.7%on this news
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx reported its second quarter 2026 financial results, highlighting advancements in its Phase 1/2a trial of GLIX1 for glioblastoma. The company noted promising preclinical data indicating GLIX1's efficacy against temozolomide-resistant tumors and its synergy with PARP inhibitors. Financially, BioLineRx maintains a cash runway into 2027, despite an increased net loss compared to the previous year.
Read more →BLRX▼ -5.8%on this newsshared move
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx Ltd. has announced a definitive agreement for a registered direct offering and concurrent private placement, raising approximately $3.75 million. The offering includes the sale of 1,348,921 American Depositary Shares (ADSs) at $2.78 each, along with warrants for additional ADSs. Proceeds will be used for research and development and general corporate purposes.
Read more →BLRXBioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx Ltd. will announce its unaudited financial results for Q2 2026 on August 31, 2026, before U.S. markets open. A conference call featuring CEO Philip Serlin will follow at 8:30 a.m. EDT. The company is focused on developing therapies for oncology and rare diseases, including its lead asset GLIX1.
Read more →BLRXBioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
BioLineRx and Hemispherian AS announced that their pre-clinical data on GLIX1's synergy with PARP inhibitors has been accepted for presentation at ESMO 2026. This research focuses on HR-proficient ovarian cancer, highlighting GLIX1's potential to enhance treatment efficacy. The presentation will take place in Madrid, Spain, from October 23-27, 2026.
Read more →BLRXBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx and Hemispherian have announced promising preclinical data showing significant synergy between GLIX1 and the PARP inhibitor olaparib in a patient-derived ovarian cancer model. The combination exhibited better efficacy than control and monotherapy arms, suggesting potential for broader use of PARP inhibitors in ovarian cancer treatment. This data supports the advancement of GLIX1 in clinical trials.
Read more →BLRX▲ +6.6%on this news
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx reported its financial results for Q1 2026, highlighting the dosing of the first patient in the Phase 1/2a clinical trial of GLIX1 for glioblastoma. The company also presented new pre-clinical data demonstrating GLIX1's effectiveness against tumor growth. Despite a net loss of $2.6 million, BioLineRx maintains a strong cash position to support ongoing development efforts.
Read more →BLRX▲ +7%on this news· ran to +26% by day 3
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS announced that two abstracts on GLIX1 will be presented at the ASCO 2026 Annual Meeting. This collaboration highlights their commitment to developing innovative therapies in oncology. The meeting will take place from May 29 to June 2, 2026, in Chicago, IL.
Read more →BLRXBioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx Ltd. will announce its unaudited financial results for Q1 2026 on May 27, 2026. A conference call featuring CEO Philip Serlin will follow at 8:30 a.m. EDT. The company is advancing its lead asset GLIX1 in a Phase 1/2a trial and has ongoing collaborations for other products.
Read more →BLRX▼ -5.9%on this newsshared move
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
BioLineRx and Hemispherian have announced promising preclinical data for GLIX1, demonstrating significant anti-tumor effects in glioblastoma models, including those resistant to temozolomide. The findings support the ongoing Phase 1/2a clinical trial aimed at treating recurrent and progressive GBM. The results indicate GLIX1's potential as a novel therapeutic option in oncology.
Read more →BLRXBioLineRx to Report 2025 Annual Results on March 23, 2026
BioLineRx Ltd. will announce its audited financial results for the year ending December 31, 2025, on March 23, 2026. A conference call featuring CEO Philip Serlin will take place at 8:30 a.m. EDT. The company is advancing its clinical pipeline, including the upcoming Phase 1/2a trial for GLIX1.
Read more →BLRX▲ +38.5%on this news
BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting
BioLineRx announced promising new data from the pilot phase of its CheMo4METPANC Phase 2 combination trial for first-line pancreatic cancer, with results to be presented at ASCO 2025. The trial evaluates motixafortide, cemiplimab, and standard chemotherapies, showing an overall response rate of 64% and four out of eleven patients remaining progression-free after more than one year. Updates reveal significant increases in CD8+ T-cell tumor infiltration, underscoring the potential of this combination therapy in treating a historically challenging cancer type. The study will expand enrollment in response to these encouraging findings.
Read more →BLRX▲ +7.4%on this news
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
BioLineRx Ltd. has announced the U.S. Patent and Trademark Office's allowance of a new composition of matter patent covering motixafortide, enhancing their intellectual property and extending patent protection until December 2041. The CEO highlighted the significance of this patent in recognizing motixafortide as a key advancement for multiple myeloma patients and other high-need indications. BioLineRx has also secured orphan drug market exclusivity for motixafortide and various international patents, bolstering their competitive position in the biopharmaceutical market.
Read more →BLRXBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
BioLineRx Ltd. announced the drawdown of the second tranche of $20 million from a $40 million non-dilutive debt financing agreement with BlackRock. The funds are earmarked to enhance the commercialization of APHEXDA for multiple myeloma and to support programs in sickle cell disease and metastatic pancreatic cancer. The detailed terms of the agreement were set out in a previous announcement from September 2022, which included favorable terms for the company. BioLineRx also reiterated its future milestones, including the expansion efforts in Asia and ongoing clinical trials.
Read more →BLRXBioLineRx to Report 2023 Annual Financial Results on March 26, 2024
BioLineRx Ltd. will announce its audited financial results for the year ending December 31, 2023, on March 26, 2024. The company will hold a conference call at 08:30 a.m. EDT, featuring remarks from CEO Philip Serlin. This event underscores the company's commitment to transparency and investor engagement.
Read more →BLRXBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
BioLineRx has finalized an exclusive licensing agreement with Guangzhou Gloria Biosciences for the development of motixafortide in Asia. The deal includes a $15 million upfront payment and potential milestones totaling up to $250 million. Gloria Biosciences will initiate a bridging study for stem cell mobilization and a Phase 2/3 trial for pancreatic cancer. This partnership aims to address significant unmet medical needs in the region.
Read more →BLRXBioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
BioLineRx announced promising results from the pilot phase of its Phase 2 clinical trial for motixafortide in first-line pancreatic cancer. Out of 11 patients, 6 experienced a partial response, with 4 confirmed cases. The trial aims to evaluate the combination of motixafortide with standard chemotherapy and PD-1 inhibitors. The findings were presented at the AACR Special Conference on Pancreatic Cancer.
Read more →BLRXBioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma | BioLineRx
BioLineRx announced FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim for mobilizing hematopoietic stem cells in multiple myeloma patients. This marks the first innovation in stem cell mobilization in the U.S. in a decade, with significant efficacy demonstrated in clinical trials.
Read more →BLRXBioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx reported its second quarter 2023 financial results, highlighting significant progress in its clinical pipeline. The company is on track for a PDUFA target action date for Motixafortide in stem cell mobilization. Additionally, BioLineRx signed an exclusive license agreement for Motixafortide in Asia and initiated a Phase 2 trial for pancreatic cancer. The CEO expressed optimism for the company's future as it transitions towards commercialization.
Read more →About BioLineRx Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next BLRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime